Demand and volumepositive · 5 filings
“Certain of our vaccines, including Comirnaty, are subject to seasonality of demand, with a greater portion of revenues and related cost of sales anticipated in the fall and winter seasons.”10-Q · Aug 4, 2026 ↗
Pfizer Inc.
PFE
Market read
Pfizer Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 5 of 25 group members are active now; 3 filing-linked outsiders are moving with the group, and 1 of 32 directly disclosed connections are confirming.
Company-0.5% todayVolume comparison unavailable
Market group5 of 25 activeBiopharmaceuticals and Care · inactive
Disclosed network1 of 8 confirmingHALO moving with the group
What would change this read
Watch this read- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- BDX remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 25 members or fewer.
Research brief
The story so far
No new filing conclusion is available. 5 of 25 group members are active now; 3 filing-linked outsiders are moving with the group, and 1 of 32 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- At least 17 of 25 durable members become active together.
- Capital-flow agreement rises above 55%.
- BDX remains aligned with the group in the next market snapshot.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations601
Usable filing statements155
Verified relationships18
Evidence supporting the case
- Demand and volume has repeated favorable evidence across 5 filings.
Evidence challenging the case
- Latest annual revenue changed -1.6% year over year.
Questions before a position
No credible peer-relative valuation comparison is available yet.
Longer-term price context
Price as of Sep 10, 2026
27.656m+1.3%12m+11.9%24m-3.0%
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$73.6B+76.8%$3.85+1.3%
2022-12-31$101.2B+37.4%$5.47+0.4%
2023-12-31$59.6B-41.1%$0.37-0.4%
2024-12-31$63.6B+6.8%$1.41-0.2%
2025-12-31$62.6B-1.6%$1.36+0.2%
What management says matters
Persistent and emerging business drivers
Foreign exchangemixed · 5 filings
“Selling, Informational and Administrative Expenses Selling, informational and administrative expenses were relatively flat in the second quarter of 2026, primarily reflecting: • lower spending of $70 million in corporate enabling functions, offset by: • an in…”10-Q · Aug 4, 2026 ↗
Product pipeline and R&Dmixed · 5 filings
“Acquired In-Process Research and Development Expenses Acquired in-process research and development expenses increased $14 million in the second quarter and $142 million in the first six months of 2026, reflecting upfront and milestone payments on certain in-l…”10-Q · Aug 4, 2026 ↗
Restructuring and cost reductionsmixed · 5 filings
“Other (Income)/Deductions—Net The unfavorable period-over-period changes of $3.0 billion in the second quarter of 2026 and $2.9 billion for the first six months of 2026 were primarily driven by (i) intangible asset impairment charges, (ii) charges for certain…”10-Q · Aug 4, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 2.5× · EV/sales 3.5×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
27.65-0.5% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for PFE. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for PFE. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind PFE
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
ARVNArvinas, Inc.partnerMay 5, 2026 ▾
“37 Approvals: PRODUCT INDICATION DATE/MARKET Veppanu (vepdegestrant) (a) Treatment of adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endo…”
ABBVAbbVie Inc.partnerFeb 26, 2026 ▾
“The U.S.”
Depended on by
ODTX17.5% of ODTXcustomerJun 17, 2026 ▾
“The Company recognized $ 0.4 million of revenue associated with the Pfizer MTA during the three months ended March 31, 2025, which is included in collaboration revenue on the condensed consolidated statements of operations and comprehensive loss.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 34 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PFE is currently a Leader in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.